Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...